Sphere Medical

On the cusp of commercialisation

Update | 22 September 2016

Share this note

The coming 12 months should mark Sphere Medical’s transition into a commercial organisation as the launch of Proxima 4 across major European markets translates into revenues.The delay in receiving the CE Mark is clearly disappointing; however, the preparations for its marketing are well advanced. Updating and rolling forward our three-phase DCF-based model yields a valuation of £21.8m, equivalent to 15.4p a share, which is up from £14.4m, 10.2p per share, previously. We again remind that we expect this to rise when the CE Mark is received to reflect the effect of the reduced investment risk.

Year-end: December201420152016E2017E
Sales (£m)
Adj. PBT (£m)(5.9)(6.0)(5.8)(5.5)
Net Income (£m)(5.3)(5.5)(5.4)(5.1)
Adj. EPS (p)(9.9)(5.3)(3.7)(3.5)
Cash (£m)3.710.02.86.7
EBITDA (£m)(5.8)(6.0)(5.8)(5.2)
Source: Trinity Delta Note: Adjusted numbers exclude share-based payments and exceptionals.
  • Interim results highlight the progress made Sphere Medical has achieved a number of critical milestones in the period. These include the appointment of a distributor in Italy, the first commercial sales in Germany and Belgium, improved connectivity with patient data systems, increased hospital evaluations (patient connections rose by 52%), and the opening of the new, dedicated manufacturing facility in St Asaph, North Wales.
  • Proxima 4 CE Mark expected shortly The CE mark certification of the Proxima 4 system remains the next key step. The process has been completed for three major elements (there are four core components that are reviewed), with only minor matters awaiting sign off on the fourth. An approval is expected shortly, with launch still due before the year end.
  • Tight cost control continues Despite the continuing preparations for Proxima 4’s commercialisation, operating expenses (£2.6m vs £3.5m in H115) were kept below budget. Marketing costs rose from £0.5m to £0.7m, with administrative expenses flat at £1.0m. Reflecting the rising visibility, product development costs of £0.1m (£1.2m H115) were expensed and £1.1m (nil in H115) was capitalised. The reported loss decreased from £3.5m to £2.6m, with loss per share down from 4.0p to 1.4p. Cash outflow was £3.3m, in line with the prior year, and net cash and equivalents was £6.6m (£12.8m H115).
  • Valuation set to rise further as risks reduce Updating our DCF model results in our valuation rising from £14.4m (10.2p a share) to £21.8m (15.4p a share). The impact is magnified as, in line with our conservative approach, our valuation excludes the company’s current cash. We also note that the CE Mark grant represents an inflection point in our model – as business risks decrease – and we intend to review our forecasts and valuation at that time


22 September 2016

Price (Sterling)12.5p
Market Cap£17.7m
Enterprise Value£11.1m
Shares in issue141.8m
12 month range6.0p-15.9p
Free float100%
Primary exchangeAIM London
Other exchangesNA
Company CodeSPHR.L
Corporate clientYes

Company description

Sphere Medical develops and commercialises medical monitoring and diagnostic equipment. Its lead product, Proxima, provides near real-time analysis of blood gases, electrolytes, and metabolites at the patient’s bedside within critical care.


Franc Gregori
+44 20 3637 5041

Mick Cooper PhD
+44 (0) 20 3637 5042

Exhibit 1: Summary of financials
Source: Sphere Medical, Trinity Delta Note: Adjusted numbers exclude share-based payments and exceptionals.


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2016 Trinity Delta Research Limited. All rights reserved.